Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Cosentyx Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Single-dose UnoReady pen (300mg)—1; Single-dose Sensoready pen (150mg)—1, 2; Single-dose prefilled syringe (300mg)—1; (150mg)—1, 2; (75mg)—1; Single-dose vial (5mL)—1
Manufacturer
Generic Availability
Mechanism of Action
Cosentyx Indications
Indications
Active psoriatic arthritis (PsA) in patients aged ≥2yrs. Active ankylosing spondylitis (AS) in adults. Active non-radiographic axial spondyloarthritis (nraxSpA) in adults with objective signs of inflammation. Active enthesitis-related arthritis (ERA) in pediatric patients aged ≥4yrs.
Cosentyx Dosage and Administration
Adult
Give by SC inj into upper arms, thighs, or any quadrant of abdomen (rotate inj site) or by IV infusion over 30mins (only for PsA, AS, and nr-axSPA). ≥18yrs: PsA with coexistent plaque psoriasis: 300mg by SC inj at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. Other PsA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; or 6mg/kg IV at Week 0, followed by 1.75mg/kg every 4 weeks thereafter. Other PsA (without a loading dose): 150mg SC every 4 weeks, consider 300mg SC every 4 weeks if PsA continues; or 1.75mg/kg IV every 4 weeks. Cosentyx may be administered with or without MTX. AS (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; or 6mg/kg IV at Week 0, followed by 1.75mg/kg every 4 weeks thereafter. AS (without a loading dose): 150mg every 4 weeks, consider 300mg SC every 4 weeks if AS continues; or 1.75mg/kg IV every 4 weeks. nraxSpA (with a loading dose): 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; or 6mg/kg IV at Week 0, followed by 1.75mg/kg every 4 weeks thereafter. nraxSpA (without a loading dose): 150mg SC every 4 weeks; or 1.75mg/kg IV every 4 weeks. For 1.75mg/kg maintenance dose in PsA, AS, and nr-axSPA: max 300mg per infusion.
Children
AS or nraxSpA (<18yrs): not established. PsA (<2yrs or <15kg) or ERA (<4yrs or <15kg): not established. Give by SC inj into upper arms, thighs, or any quadrant of abdomen (rotate inj site). PsA (≥2yrs): ≥15–<50kg: 75mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; ≥50kg: 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter. Cosentyx may be administered with or without MTX. ERA (≥4yrs): ≥15–<50kg: 75mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter; ≥50kg: 150mg by SC inj at Weeks 0, 1, 2, 3, and 4 and every 4 weeks thereafter.
Cosentyx Contraindications
Not Applicable
Cosentyx Boxed Warnings
Not Applicable
Cosentyx Warnings/Precautions
Warnings/Precautions
May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. May need to discontinue if severe eczematous eruptions occur. Complete all immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.
Cosentyx Pharmacokinetics
Absorption
Peak mean (± SD) serum concentrations (Cmax) of 13.7 ± 4.8 mcg/mL and 27.3 ± 9.5 mcg/mL, respectively, were reached by ~6 days post dose after administration of a single SC dose of 150 mg or 300 mg secukinumab.
Patients who received the Sensoready pens were observed to have 23–30% higher mean trough concentrations vs those who received the lyophilized powder and 23–26% higher than those who received the prefilled syringe.
Steady-state concentrations were achieved by Week 24 after the every 4-week dosing regimens.
Bioavailability ranged from 55–77%.
Distribution
Mean volume of distribution: 7.10–8.60 L.
Elimination
Half-life: 22–31 days. Mean systemic clearance: 0.14–0.22 L/day.
Cosentyx Interactions
Interactions
Cosentyx Adverse Reactions
Adverse Reactions
Cosentyx Clinical Trials
See Literature
Cosentyx Note
Not Applicable
Cosentyx Patient Counseling
See Literature
Cosentyx Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Single-dose UnoReady pen (300mg)—1; Single-dose Sensoready pen (150mg)—1, 2; Single-dose prefilled syringe (300mg)—1; (150mg)—1, 2; (75mg)—1; Single-dose vial (5mL)—1
Manufacturer
Generic Availability
Mechanism of Action
Cosentyx Indications
Indications
Moderate to severe hidradenitis suppurativa.
Cosentyx Dosage and Administration
Adult
Give by SC inj into upper arms, thighs, or any quadrant of abdomen (rotate inj site). ≥18yrs: 300mg at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. If inadequate response, consider 300mg every 2 weeks.
Children
Not established.
Cosentyx Contraindications
Not Applicable
Cosentyx Boxed Warnings
Not Applicable
Cosentyx Warnings/Precautions
Warnings/Precautions
May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. May need to discontinue if severe eczematous eruptions occur. Complete all immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.
Cosentyx Pharmacokinetics
Absorption
Peak mean (± SD) serum concentrations (Cmax) of 13.7 ± 4.8 mcg/mL and 27.3 ± 9.5 mcg/mL, respectively, were reached by ~6 days post dose after administration of a single SC dose of 150 mg or 300 mg secukinumab.
Patients who received the Sensoready pens were observed to have 23–30% higher mean trough concentrations vs those who received the lyophilized powder and 23–26% higher than those who received the prefilled syringe.
Steady-state concentrations were achieved by Week 24 after the every 4-week dosing regimens.
Bioavailability ranged from 55–77%.
Distribution
Mean volume of distribution: 7.10–8.60 L.
Elimination
Half-life: 22–31 days. Mean systemic clearance: 0.14–0.22 L/day.
Cosentyx Interactions
Interactions
Cosentyx Adverse Reactions
Adverse Reactions
Cosentyx Clinical Trials
See Literature
Cosentyx Note
Not Applicable
Cosentyx Patient Counseling
See Literature
Cosentyx Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Single-dose UnoReady pen (300mg)—1; Single-dose Sensoready pen (150mg)—1, 2; Single-dose prefilled syringe (300mg)—1; (150mg)—1, 2; (75mg)—1; Single-dose vial (5mL)—1
Manufacturer
Generic Availability
Mechanism of Action
Cosentyx Indications
Indications
Cosentyx Dosage and Administration
Adult
Give by SC inj into upper arms, thighs, or any quadrant of abdomen; rotate inj site. ≥18yrs: 300mg at Weeks 0, 1, 2, 3, and 4 then 300mg every 4 weeks. For some patients, 150mg SC dose may be acceptable.
Children
<6yrs: not established. Give by SC inj into upper arms, thighs, or any quadrant of abdomen; rotate inj site. Administer at Weeks 0, 1, 2, 3, and 4 then every 4 weeks thereafter. ≥6yrs (<50kg): 75mg; (≥50kg): 150mg.
Cosentyx Contraindications
Not Applicable
Cosentyx Boxed Warnings
Not Applicable
Cosentyx Warnings/Precautions
Warnings/Precautions
May increase risk of infections. Chronic or history of recurrent infection. If a serious infection develops, monitor closely and discontinue until resolves. History of latent or active TB; consider anti-TB therapy prior to initiation. Evaluate for TB infection prior to initiation. Monitor for active TB during and after therapy. Patients with active TB infection: do not initiate. Inflammatory bowel disease; monitor. Discontinue if anaphylaxis or serious allergic reactions occur. May need to discontinue if severe eczematous eruptions occur. Complete all immunizations based on current guidelines prior to initiation. Latex allergy (Sensoready pen and prefilled syringe only). Pregnancy. Nursing mothers.
Cosentyx Pharmacokinetics
Absorption
Peak mean (± SD) serum concentrations (Cmax) of 13.7 ± 4.8 mcg/mL and 27.3 ± 9.5 mcg/mL, respectively, were reached by ~6 days post dose after administration of a single SC dose of 150 mg or 300 mg secukinumab.
Patients who received the Sensoready pens were observed to have 23–30% higher mean trough concentrations vs those who received the lyophilized powder and 23–26% higher than those who received the prefilled syringe.
Steady-state concentrations were achieved by Week 24 after the every 4-week dosing regimens.
Bioavailability ranged from 55–77%.
Distribution
Mean volume of distribution: 7.10–8.60 L.
Elimination
Half-life: 22–31 days. Mean systemic clearance: 0.14–0.22 L/day.
Cosentyx Interactions
Interactions
Cosentyx Adverse Reactions
Adverse Reactions
Cosentyx Clinical Trials
See Literature
Cosentyx Note
Not Applicable
Cosentyx Patient Counseling
See Literature
Images
